Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

Group 1 - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025 [1] - The lawsuit alleges that uniQure misled investors regarding the likelihood of FDA approval for its leading drug candidate, AMT-130, by failing to disclose that the pivotal study design was not fully approved by the FDA [1] - Following the announcement on November 3, 2025, regarding FDA feedback, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29 [1] Group 2 - Robbins LLP is also investigating a class action lawsuit against POMDoctor Ltd. for investors who acquired securities between October 9, 2025, and December 11, 2025 [1] - Another class action has been filed against Inovio Pharmaceuticals, Inc. for investors who purchased securities between October 10, 2023, and December 26, 2025 [1] - A class action lawsuit has been initiated against Masonite International Corporation for sellers of common stock between June 5, 2023, and February 8, 2024 [1]